← Leaderboards
Pinar Ozden Eser
Harvard Medical School
$102,555
Attributed
$102,555
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $35.7K · FY2015–17$50K$37.5K$25K$12.5K$0
'15
'16
'17
Funding mix
By agency
NIH$102,555 · 1
By mechanism
F31$102,555 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard Medical School
Same institution · by research overlap
- Jeffrey R. Starke$2,653,443
- Jerome Timothy Galea$2,653,443
- Aedin C Culhane$2,653,443
- Ann Chesney Miller$2,653,443
- Priscilla Li-Ning Yang$20,185,658
Others in their field
Top investigators on “Epidermal Growth Factor”
- Norman Wolmark · Nsabp Foundation, Inc.$27,726,714
- Walter John Curran · Thomas Jefferson University$26,641,549
- Robert J Coffey · Vanderbilt University$24,542,527
- Pasi A Janne · Stanford University$23,416,433
- John H Sampson · Duke University$22,281,972
- Elaine Fuchs · University Of Chicago$21,320,660
Research focus
Epidermal Growth FactorDrug TargetingDrug ResistanceEngineeringBaseCellsBiologyAccountingClinical Decision-MakingCancer PatientCell LineClinical InvestigationClinical TrialsClone CellsClustered Regularly Interspaced Short Palindromic RepeatsCodon NucleotidesCollaborationsClinicCultured CellsDesignDetectionDoseClinical EfficacyEpidermal Growth Factor Receptor
Grant awards (3)
EGFR T790M-mediated drug resistance in non-small cell lung cancer$31,649
F31 · FY2017 · CA · contact PI
EGFR T790M-mediated drug resistance in non-small cell lung cancer$35,681
F31 · FY2016 · CA · contact PI
EGFR T790M-mediated drug resistance in non-small cell lung cancer$35,225
F31 · FY2015 · CA · contact PI